ABTECT - Maintenance
Trial details
- Registry ID
- NCT05535946
- Drugs studied
- ABX464
TrialRedline tracks 13 clinical trials sponsored by Abivax S.A.: 3 Phase 3, 1 Phase 2 / 3, 8 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ABTECT - MaintenanceNCT05535946 | ABX464 | Active not recruiting | 2026-04-28Actual |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203 | ABX464 | Completed | 2025-06-24Actual |
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216 | ABX464 | Completed | 2025-06-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038 | ABX464 | Terminated | 2021-03-05Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaNCT03897543 | ABX196 | Completed | 2022-04-14Actual |
Names as written in the registry records.
NCT05507216 · Abivax S.A.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8. After: Measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8.
NCT05507203 · Abivax S.A.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8. After: Measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8.
NCT05535946 · Abivax S.A.
Before: Estimated. After: Actual.
Before: Apr 2026. After: 28 Apr 2026.
Before: Mar 2026. After: Mar 2028.
NCT04393038 · Abivax S.A.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive. After: Measure: Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period..